Phio Pharmaceuticals Corp. PHIOW 深 沪
等待开盘 09-18 09:30:00 美东时间
0.0232
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0232
- 总市值 10.63万
- 52周最高 1.16
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.006
- 委 比 0.00%
- 总股本 458.09万
- 历史最高 1.16
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.006
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phio Pharmaceuticals Stockholders Approve Key 2025 Proposals
The latest announcement is out from Phio Pharmaceuticals ( ($PHIO) ). At the An...
09-16 04:39
Phio Pharmaceuticals to Discuss Strategy for PH-762 Skin Cancer Drug at Investor Conference
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced
09-03 19:51
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
08-15 19:17
Phio Pharma Q2 EPS $(0.45) Misses $(0.36) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.36) by 25 percent. This is a 87.57 percent increase over losses of $(3.62) per share from the
08-15 04:19
Phio Pharmaceuticals Issues New Warrants for $2.5M
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an update. On July 25, 2025, Phi...
07-31 04:51
Phio Pharmaceuticals Announces New Manufacturing Agreement
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an announcement. On July 25, 202...
07-26 01:57
Phio Pharmaceuticals Reports Complete Tumor Clearance In cSCC Patient And Partial Response In Stage 4 Merkel Cell Carcinoma In Ongoing PH-762 Phase 1b Trial
Complete Pathologic Response in patient with cutaneous squamous cell carcinomaPartial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio
07-26 00:40
1. Phio Pharma CEO To Present New Skin Cancer Data On Groundbreaking Gene-Silencing Therapy PH-762
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
06-24 19:47
HC Wainwright & Co. Assumes Phio Pharma at Buy, Announces Price Target of $14
HC Wainwright & Co. analyst Joseph Pantginis assumes Phio Pharma (NASDAQ:PHIO) with a Buy rating and announces Price Target of $14.
06-05 19:11
Phio Pharma To Present Update On Proprietary INTASYL Sirna Technology And Progress On On-Going Clinical Trial With Lead Compound PH-762 For Treatment Of Skin Cancers
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA
05-19 19:50
